AIIMS Ethics Committee gives approval to conduct clinical human trials of indigenously developed COVID-19 vaccine 'Covaxin'
Guwahati: The All India Institute of Medical Sciences (AIIMS) Ethics Committee on Saturday gave its approval to conduct clinical human trials of the indigenously developed COVID-19 vaccine 'Covaxin' from Monday.
India’s top drug regulator recently gave the green signal for human trials for Covaxin. The ethics committee raised some concerns a few days ago with regards to the trial. All these concerns were addressed. Covaxin has been developed by Bharat Biotech, based in Hyderabad, in collaboration with the National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR).
Professor at Centre for Community Medicine at AIIMS Dr Sanjay Rai said that the hospital will start enrolling healthy individuals from Monday onwards. They are going to select healthy participants with no history of COVID-19 and with no comorbidities under the age group of 18-55 years. He even stated that this would be a randomised, double-blind, placebo-controlled clinical trial.
Moreover, any individual can participate in the trial and can send in an email on Ctaiims.email@example.com or even send an SMS or call on 7428847499. Additionally, in the first and second phases, AIIMS Delhi will select only 100 participants out of 375 volunteers. The remaining volunteers will participate at other sites.
Rai said that they have already registered a few volunteers for the trial and from Monday their team will start the health screening before giving them the vaccine. It must also be noted that the trial is taking place in 12 places across India as per the ICMR. Additionally, trials have already started in AIIMS Patna and some other places.